Bio Pharma Dive
MARCH 4, 2024
The deal gives the German pharma partial rights to a closely watched medicine for transthyretin amyloidosis cardiomyopathy that analysts expect to become a multibillion-dollar product.
Pharmaceutical Technology
MARCH 4, 2024
In late 2023, the Medicines and Healthcare products Regulatory Agency approved Vertex’s Casgevy, which became the inaugural clustered regularly interspaced short palindromic repeats (CRISPR)-based drug for the haematological indications beta thalassemia and sickle cell disease (SCD).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
MARCH 4, 2024
The two pharmacy retailers will begin dispensing mifepristone in some states weeks before the start of a Supreme Court case that will decide how widely the pill can be accessed.
Pharmaceutical Technology
MARCH 4, 2024
The EMA has validated the jointly developed TROP2-directed therapy for patients with breast or lung cancer following positive Phase III data.
Bio Pharma Dive
MARCH 4, 2024
The updated results show that responses to the drug, which is currently in late-stage testing, deepened with time, helping the company rebound from an earlier setback.
Pharmaceutical Technology
MARCH 4, 2024
For Rare Disease Day, several panels organised by the FDA discussed the importance overcoming accessibility barriers during drug development.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
MARCH 4, 2024
Sandoz has concluded the acquisition of the US biosimilar CIMERLI from Coherus BioSciences, bolstering ophthalmology and biosimilar expertise.
Bio Pharma Dive
MARCH 4, 2024
The rejection is the latest setback in the pharmaceutical industry’s efforts to use the courts to challenge Medicare’s new pricing powers.
Pharmaceutical Technology
MARCH 4, 2024
How many patents did F. Hoffmann-La Roche submit related to advanced materials last quarter, and how many were granted? Discover the latest information here.
pharmaphorum
MARCH 4, 2024
Inhaled cannabinoids have been shown to perform better than placebo in providing pain relief for people suffering from acute migraine in a clinical trial
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
MARCH 4, 2024
The China's NMPA has granted approval for CARsgen Therapeutics' NDA for zevorcabtagene autoleucel to treat multiple myeloma.
Fierce Pharma
MARCH 4, 2024
When Pfizer completed its $43 billion buyout of Seagen in December | Less than three months after completing its $43 billion acquisition of Seagen, Pfizer has confirmed a report that it is shutting down construction of a $350 million manufacturing facility in Everett, Washington. The decision will affect 120 employees working on the initial setup of the site, the company said.
Pharmaceutical Technology
MARCH 4, 2024
FogPharma has secured $145m in a Series E financing round to support the clinical development of its cancer therapy, FOG-001.
Drug Discovery World
MARCH 4, 2024
In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. Both medications tested in the trial support immune responses against tumour cells. CS1002 increases the activation and proliferation of T immune cells by binding to a T cell receptor called CTLA-4.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
MARCH 4, 2024
The study looked at medical records of over three million diabetic patients and almost one million non-diabetic patients.
Bio Pharma Dive
MARCH 4, 2024
How are knowledge graphs changing the path of drug discovery?
Pharmaceutical Technology
MARCH 4, 2024
The US FDA has granted full approval for Johnson & Johnson's (J&J) RYBREVANT for types of NSCLC.
Bio Pharma Dive
MARCH 4, 2024
Panalgo’s Meg Richards and Mike Munsell discuss how AI and ML are transforming the healthcare research landscape.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
MARCH 4, 2024
How many patents did F. Hoffmann-La Roche submit related to internet of things last quarter, and how many were granted? Discover the latest information here.
Fierce Pharma
MARCH 4, 2024
A little more than half a year after winning a historic over-the-counter nod, Perrigo’s nonprescription birth control pill Opill is set to hit store shelves in the “coming weeks.” | A little more than half a year after winning a historic over-the-counter nod, Perrigo’s nonprescription birth control pill Opill is set to hit store shelves in the “coming weeks.
Pharmaceutical Technology
MARCH 4, 2024
How many patents did F. Hoffmann-La Roche submit related to cybersecurity last quarter, and how many were granted? Discover the latest information here.
pharmaphorum
MARCH 4, 2024
Explore the future of drug manufacturing with dark factories, robotic and automated facilities that promise efficiency and innovation. Learn how these advancements are shaping a bright future for the pharmaceutical industry.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
MARCH 4, 2024
How many patents did F. Hoffmann-La Roche submit related to robotics last quarter, and how many were granted? Discover the latest information here.
Fierce Pharma
MARCH 4, 2024
After decades of research into respiratory syncytial virus (RSV), Pfizer and GSK’s groundbreaking vaccines made waves as the first immunizations against the common respiratory illness. | After a preliminary analysis found a potentially higher risk of Guillain-Barré syndrome following RSV vaccination in older adults, GSK and Pfizer said they will conduct further safety studies.
Pharmaceutical Technology
MARCH 4, 2024
How many patents did F. Hoffmann-La Roche submit related to digitalization last quarter, and how many were granted? Discover the latest information here.
Pharma Tutor
MARCH 4, 2024
Architect of Indian Pharmacy Education : Prof. Mahadev Lal Schroff admin Mon, 03/04/2024 - 16:44 ABOUT AUTHOR Dr. R. S. Thakur Former Secretary, Pharmacy Council of India. Email : drramsthakur@gmail.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
MARCH 4, 2024
How many patents did F. Hoffmann-La Roche submit related to big data last quarter, and how many were granted? Discover the latest information here.
pharmaphorum
MARCH 4, 2024
The clock has started ticking in the EU on two marketing applications for AstraZeneca and Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate datopotamab deruxtecan in breast and lung cancer. The EMA has validated the two parallel applications for the drug, also known as Dato-DXd, in adults with previously treated non-small cell lung cancer (NSCLC) and hormone receptor-positive, HER2-negative breast cancer.
Pharmaceutical Technology
MARCH 4, 2024
How many patents did F. Hoffmann-La Roche submit related to mobile last quarter, and how many were granted? Discover the latest information here.
Pharma Times
MARCH 4, 2024
Around 900,000 people in the UK are affected by the progressive neurodegenerative disease
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
280 
Let's personalize your content